Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Potential Peptide Therapeutic Derived from the Juxtamembrane Domain of the Epidermal Growth Factor Receptor.

Autor: Boran, Aislyn D. W.¹ (AUTHOR), Seco, Joseph¹ (AUTHOR), Jayaraman, Vinodh¹ (AUTHOR), Jayaraman, Gomathi¹ (AUTHOR), Zhao, Shan¹ (AUTHOR), Reddy, Sushmitha¹ (AUTHOR), Chen, Yibang¹ (AUTHOR), Iyengar, Ravi¹ (AUTHOR) ravi.iyengar@mssm.edu

Publikováno v: PLoS ONE. Nov2012, Vol. 7 Issue 11, p1-15. 15p.

Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.

Autor: Norgard RJ; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Budhani P; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., O'Brien SA; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Xia Y; Global Computational Biology and Digital Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Egan JN; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Flynn B; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Tagore JR; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Seco J; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Peet GW; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Mikucka A; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Wasti R; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Chan LC; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Hinkel M; Late Stage Cancer Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Martinez-Morilla S; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Pignatelli J; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Trapani F; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Corse E; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Feng D; Global Computational Biology and Digital Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Kostyrko K; Late Stage Cancer Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Hofmann MH; Cancer Pharmacology and Disease Positioning Department, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Liu K; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut., Kashyap AS; Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Jun 21; Vol. 4 (6), pp. 1548-1560.